RecruitingPhase 2NCT06389799

A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)

Studying Dedifferentiated liposarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Lund University Hospital
Intervention
Pemigatinib(drug)
Enrollment
33 enrolled
Eligibility
18-100 years · All sexes
Timeline
20242028

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06389799 on ClinicalTrials.gov

Other trials for Dedifferentiated liposarcoma

Additional recruiting or active studies for the same condition.

See all trials for Dedifferentiated liposarcoma

← Back to all trials